Stock SOAN ANGIOSOMA
Add to a list
To use this feature you must be a member
Log inSign up

Financials ANGIOSOMA OTC Markets

Equities

SOAN

US03476L1026

Biotechnology & Medical Research

End-of-day quote OTC Markets
Other stock markets
 23:00:00 04/02/2024 GMT 		5-day change 1st Jan Change
0.0009 USD -.--% Intraday chart for ANGIOSOMA +20.00% -.--%
03-12 GlobeStar Therapeutics Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
2021 Globestar Therapeutics Corporation Reports Earnings Results for the Third Quarter Ended June 30, 2021 CI

Valuation

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Capitalization 1 1.55 1.006 2.966 16.32 2.673 1.793
Enterprise Value (EV) 1 1.744 1.019 3.04 16.42 2.825 2.159
P/E ratio -1.7 x -0.27 x -3.74 x -1.46 x -1.56 x -0.76 x
Yield - - - - - -
Capitalization / Revenue 1,741 x 2,366 x 38,523 x - - -
EV / Revenue 1,959 x 2,398 x 39,479 x - - -
EV / EBITDA -4.97 x -3.23 x -10.1 x -1.81 x -2.24 x -
EV / FCF 426 x -28.2 x -18.5 x 6.36 x 19.4 x -
FCF Yield 0.23% -3.55% -5.41% 15.7% 5.16% -
Price to Book -0.44 x -0.19 x -4.49 x -22.8 x -2.23 x -1.25 x
Nbr of stocks (in thousands) 63,004 170,467 436,218 551,496 722,327 996,120
Reference price 2 0.0246 0.005900 0.006800 0.0296 0.003700 0.001800
Announcement Date 03/01/19 31/12/19 03/12/20 05/01/22 09/01/23 19/01/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Net sales 1 0.00089 0.000425 0.000077 - - -
EBITDA 1 -0.3509 -0.3154 -0.3023 -9.093 -1.264 -
EBIT 1 -0.3511 -0.3159 -0.3037 -9.094 -1.265 -1.864
Operating Margin -39,444.04% -74,322.35% -394,377.92% - - -
Earnings before Tax (EBT) 1 -0.8167 -0.6751 -0.5417 -9.802 -1.488 -1.949
Net income 1 -0.8167 -0.6751 -0.5417 -9.802 -1.488 -1.949
Net margin -91,768.65% -158,840.47% -703,546.75% - - -
EPS 2 -0.0145 -0.0217 -0.001817 -0.0203 -0.002367 -0.002356
Free Cash Flow 1 0.004095 -0.0361 -0.1643 2.582 0.1458 -
FCF margin 460.11% -8,505.18% -213,392.21% - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 03/01/19 31/12/19 03/12/20 05/01/22 09/01/23 19/01/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Net Debt 1 0.19 0.01 0.07 0.1 0.15 0.37
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -0.5519 x -0.0423 x -0.2435 x -0.011 x -0.1205 x -
Free Cash Flow 1 0 -0.04 -0.16 2.58 0.15 -
ROE (net income / shareholders' equity) 109% 86.8% 80.6% 1,415% 155% 148%
ROA (Net income/ Total Assets) -294% -148% -164% -11,857% -9,962% -
Assets 1 0.2779 0.4564 0.3312 0.0827 0.0149 -
Book Value Per Share 2 -0.0600 -0.0300 -0 -0 -0 -0
Cash Flow per Share 2 0 0 0 0 0 -
Capex 1 0 - 0 - - -
Capex / Sales 158.65% - 2,314.29% - - -
Announcement Date 03/01/19 31/12/19 03/12/20 05/01/22 09/01/23 19/01/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+39.60% 53.67B
LONZA GROUP AG Stock Lonza Group AG
+33.67% 38.86B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.01% 38.76B
CELLTRION, INC. Stock Celltrion, Inc.
-10.77% 27.27B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.45% 25.91B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-17.30% 20.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+34.50% 12.78B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.48% 12.18B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-3.08% 11.96B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GSTC Stock
  4. SOAN Stock
  5. Financials ANGIOSOMA
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW